Table 4.
Diagnostic Accuracy of Prognostic Clinical Decision Support Tool for Identifying Patients Likely to Respond to Vedolizumab using CRP as categorical value
| Sensitivity (95% CI) |
Specificity (95% CI) |
PLR (95% CI) |
NLR (95% CI) |
|
|---|---|---|---|---|
| 13 points | ||||
| Clinical remission after 26 weeks | 92% (85–97%) |
25% (20–31%) |
1.24 (1.12–1.36) |
0.30 (0.14–0.64) |
| Corticosteroid-free remission after 26 weeks* | 94% (81–99%) |
30% (22–38%) |
1.34 (1.17–1.54) |
0.19 (0.05–0.76) |
| Mucosal healing after 26 weeks | 98% (88–100%) |
30% (23–37%) |
1.39 (1.25–1.54) |
0.08 (0.01–0.55) |
| Deep Remission after 26 weeks | 100% (88–100%) |
28% (22–35%) |
1.39 (1.28–1.51) |
0.00 (−) |
| Corticosteroid-Free Deep Remission after 26 weeks* | 100% (75–100%) |
31% (23–41%) |
1.45 (1.28–1.65) |
0.00 (−) |
| 19 points | ||||
| Clinical remission after 26 weeks | 33% (24–44%) |
80% (74–85%) |
1.65 (1.12–2.42) |
0.84 (0.72–0.98) |
| Corticosteroid-free remission after 26 weeks* | 37% (22–55%) |
77% (69–84%) |
1.62 (0.95–2.75) |
0.82 (0.62–1.07) |
| Mucosal healing after 26 weeks | 40% (25–56%) |
80% (74–86%) |
2.01 (1.26–3.20) |
0.75 (0.59–0.97) |
| Deep Remission after 26 weeks | 38% (21–58%) |
79% (73–84%) |
1.78 (1.05–3.04) |
0.79 (0.59–1.06) |
| Corticosteroid-Free Deep Remission after 26 weeks* | 46% (19–75%) |
78% (69–85%) |
2.07 (1.05–4.09) |
0.69 (0.42–1.16) |
*
Performed for subset of patients who were on corticosteroids at baseline. Stratified analysis by baseline steroid dose performed with no significant changes in performance.
PLR, positive likelihood ratio; NLR, negative likelihood ratio.